Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2022

Rajappa P, Eng KW, Bareja R, Bander ED, Yuan M, Dua A, et al. Utility of multimodality molecular profiling for pediatric patients with central nervous system tumors. Neurooncol Adv. 2022;4(1):vdac031.

Kim J, Rustam S, Mosquera JM, Randell SH, Shaykhiev R, Rendeiro AF, et al. Unsupervised discovery of tissue architecture in multiplexed imaging. Nat Methods. 2022;19(12):1653-1661.

Bruehl FK, Kim AS, Li MM, Lindeman NI, Moncur JT, Souers RJ, et al. Tiered Somatic Variant Classification Adoption Has Increased Worldwide With Some Practice Differences Based on Location and Institutional Setting. Arch Pathol Lab Med. 2022;146(7):822-832.

Zhang T, Zhang G, Chen X, Chen Z, Tan AY, Lin A, et al. Low-dose carbon monoxide suppresses metastatic progression of disseminated cancer cells. Cancer Lett. 2022;546:215831.

Rodriguez-Flores JL, Messai-Badji R, Robay A, Temanni R, Syed N, Markovic M, et al. The QChip1 knowledgebase and microarray for precision medicine in Qatar. NPJ Genom Med. 2022;7(1):3.

Pillai AA, Kriss M, Al-Adra DP, Chadha RM, Cushing MM, Farsad K, et al. Coagulopathy and hemostasis management in patients undergoing liver transplantation: Defining a dynamic spectrum across phases of care. Liver Transpl. 2022;28(10):1651-1663.

Gardner A, Alvarez J, Genovese C, Snodgrass R, Kopparthy V, Erickson D, et al. Simplified detection of Epstein-Barr virus for diagnosis of endemic Burkitt lymphoma. Blood Adv. 2022;6(12):3650-3654.

Temkin SM, Smeltzer MP, Dawkins MD, Boehmer LM, Senter L, Black DR, et al. Improving the quality of care for patients with advanced epithelial ovarian cancer: Program components, implementation barriers, and recommendations. Cancer. 2022;128(4):654-664.

Shouval R, Fein JA, Cho C, Avecilla ST, Ruiz J, Tomas AA, et al. The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT. Blood Adv. 2022;6(5):1525-1535.

Xiang G, Wang S, Chen L, Song M, Song X, Wang H, et al. UBR5 targets tumor suppressor CDC73 proteolytically to promote aggressive breast cancer. Cell Death Dis. 2022;13(5):451.